{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:23:18Z","timestamp":1791235398651,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00259-017-3879-x","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:10:22Z","timestamp":1511741422000},"page":"1041-1051","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5"],"prefix":"10.1007","volume":"45","author":[{"given":"Geoffrey","family":"Warnock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sommerauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjing","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Pla Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Geistlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Treyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Schibli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie D.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon M.","family":"Ametamey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"3879_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/088307380401900507","volume":"19","author":"TA Simeone","year":"2004","unstructured":"Simeone TA, Sanchez RM, Rho JM. Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system. J Child Neurol. 2004;19:343\u2013360; discussion 61. https:\/\/doi.org\/10.1177\/088307380401900507 .","journal-title":"J Child Neurol"},{"key":"3879_CR2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1152\/jn.1995.74.1.122","volume":"74","author":"RW Gereau","year":"1995","unstructured":"Gereau RW, Conn PJ. Roles of specific metabotropic glutamate receptor subtypes in regulation of hippocampal CA1 pyramidal cell excitability. J Neurophysiol. 1995;74:122\u20139.","journal-title":"J Neurophysiol"},{"key":"3879_CR3","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1523\/JNEUROSCI.20-09-03085.2000","volume":"20","author":"SR Bradley","year":"2000","unstructured":"Bradley SR, Marino MJ, Wittmann M, Rouse ST, Awad H, Levey AI, et al. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata. J Neurosci. 2000;20:3085\u201394.","journal-title":"J Neurosci"},{"key":"3879_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1742-7843.2005.pto_156.x","volume":"97","author":"A Ritzen","year":"2005","unstructured":"Ritzen A, Mathiesen JM, Thomsen C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol. 2005;97:202\u201313. https:\/\/doi.org\/10.1111\/j.1742-7843.2005.pto_156.x .","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3879_CR5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0022-3565(24)39029-9","volume":"295","author":"WP Spooren","year":"2000","unstructured":"Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther. 2000;295:1267\u201375.","journal-title":"J Pharmacol Exp Ther"},{"key":"3879_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/sj.bjp.0703923","volume":"132","author":"E Tatarczynska","year":"2001","unstructured":"Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001;132:1423\u201330. https:\/\/doi.org\/10.1038\/sj.bjp.0703923 .","journal-title":"Br J Pharmacol"},{"key":"3879_CR7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0169-328X(98)00063-1","volume":"56","author":"T Ohnuma","year":"1998","unstructured":"Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res. 1998;56:207\u201317.","journal-title":"Brain Res Mol Brain Res"},{"key":"3879_CR8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0163-7258(00)00098-X","volume":"88","author":"ST Rouse","year":"2000","unstructured":"Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther. 2000;88:427\u201335.","journal-title":"Pharmacol Ther"},{"key":"3879_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nn0901-873","volume":"4","author":"C Chiamulera","year":"2001","unstructured":"Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci. 2001;4:873\u20134. https:\/\/doi.org\/10.1038\/nn0901-873 .","journal-title":"Nat Neurosci"},{"key":"3879_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(00)00113-1","volume":"40","author":"K Walker","year":"2001","unstructured":"Walker K, Bowes M, Panesar M, Davis A, Gentry C, Kesingland A, et al. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology. 2001;40:1\u20139.","journal-title":"Neuropharmacology"},{"key":"3879_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0028-3908(00)00114-3","volume":"40","author":"K Walker","year":"2001","unstructured":"Walker K, Reeve A, Bowes M, Winter J, Wotherspoon G, Davis A, et al. mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology. 2001;40:10\u20139.","journal-title":"Neuropharmacology"},{"key":"3879_CR12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0304-3940(03)00259-3","volume":"342","author":"ML Sotgiu","year":"2003","unstructured":"Sotgiu ML, Bellomi P, Biella GE. The mGluR5 selective antagonist 6-methyl-2-(phenylethynyl)-pyridine reduces the spinal neuron pain-related activity in mononeuropathic rats. Neurosci Lett. 2003;342:85\u20138.","journal-title":"Neurosci Lett"},{"key":"3879_CR13","first-page":"698","volume":"47","author":"SM Ametamey","year":"2006","unstructured":"Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S, et al. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med. 2006;47:698\u2013705.","journal-title":"J Nucl Med"},{"key":"3879_CR14","first-page":"247","volume":"48","author":"SM Ametamey","year":"2007","unstructured":"Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M, et al. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med. 2007;48:247\u201352.","journal-title":"J Nucl Med"},{"key":"3879_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.biopsych.2012.07.030","volume":"73","author":"K Hefti","year":"2013","unstructured":"Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM, et al. Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep. Biol Psychiatry. 2013;73:161\u20138. https:\/\/doi.org\/10.1016\/j.biopsych.2012.07.030 .","journal-title":"Biol Psychiatry"},{"key":"3879_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1073\/pnas.1210984110","volume":"110","author":"F Akkus","year":"2013","unstructured":"Akkus F, Ametamey SM, Treyer V, Burger C, Johayem A, Umbricht D, et al. Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography. Proc Natl Acad Sci U S A. 2013;110:737\u201342. https:\/\/doi.org\/10.1073\/pnas.1210984110 .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3879_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/mp.2013.51","volume":"19","author":"LM Hulka","year":"2014","unstructured":"Hulka LM, Treyer V, Scheidegger M, Preller KH, Vonmoos M, Baumgartner MR, et al. Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans. Mol Psychiatry. 2014;19:625\u201332. https:\/\/doi.org\/10.1038\/mp.2013.51 .","journal-title":"Mol Psychiatry"},{"key":"3879_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.biopsych.2014.06.024","volume":"77","author":"C DeLorenzo","year":"2015","unstructured":"DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, et al. In vivo ketamine-induced changes in [(1)(1)C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry. 2015;77:266\u201375. https:\/\/doi.org\/10.1016\/j.biopsych.2014.06.024 .","journal-title":"Biol Psychiatry"},{"key":"3879_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.neuroimage.2014.04.061","volume":"98","author":"MS Milella","year":"2014","unstructured":"Milella MS, Marengo L, Larcher K, Fotros A, Dagher A, Rosa-Neto P, et al. Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study. NeuroImage. 2014;98:195\u2013202. https:\/\/doi.org\/10.1016\/j.neuroimage.2014.04.061 .","journal-title":"NeuroImage"},{"key":"3879_CR20","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.2967\/jnumed.108.056291","volume":"49","author":"AK Brown","year":"2008","unstructured":"Brown AK, Kimura Y, Zoghbi SS, Simeon FG, Liow JS, Kreisl WC, et al. Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET. J Nucl Med. 2008;49:2042\u20138. https:\/\/doi.org\/10.2967\/jnumed.108.056291 .","journal-title":"J Nucl Med"},{"key":"3879_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/jcbfm.2012.195","volume":"33","author":"JM Sullivan","year":"2013","unstructured":"Sullivan JM, Lim K, Labaree D, Lin SF, McCarthy TJ, Seibyl JP, et al. Kinetic analysis of the metabotropic glutamate subtype 5 tracer [(18)F]FPEB in bolus and bolus-plus-constant-infusion studies in humans. J Cereb Blood Flow Metab. 2013;33:532\u201341. https:\/\/doi.org\/10.1038\/jcbfm.2012.195 .","journal-title":"J Cereb Blood Flow Metab"},{"key":"3879_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/syn.21890","volume":"70","author":"G Leurquin-Sterk","year":"2016","unstructured":"Leurquin-Sterk G, Postnov A, de Laat B, Casteels C, Celen S, Crunelle CL, et al. Kinetic modeling and long-term test-retest reproducibility of the mGluR5 PET tracer 18F-FPEB in human brain. Synapse. 2016;70:153\u201362. https:\/\/doi.org\/10.1002\/syn.21890 .","journal-title":"Synapse"},{"key":"3879_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2967\/jnumed.114.151332","volume":"56","author":"NA Stephenson","year":"2015","unstructured":"Stephenson NA, Holland JP, Kassenbrock A, Yokell DL, Livni E, Liang SH, et al. Iodonium ylide-mediated radiofluorination of 18F-FPEB and validation for human use. J Nucl Med. 2015;56:489\u201392. https:\/\/doi.org\/10.2967\/jnumed.114.151332 .","journal-title":"J Nucl Med"},{"key":"3879_CR24","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1055\/s-0033-1338843","volume":"45","author":"S Milicevic Sephton","year":"2013","unstructured":"Milicevic Sephton S, Mu L, Dragic M, M\u00fcller A, Kr\u00e4mer SD, Schibli R, et al. Synthesis and in vitro evaluation of E and Z isomers of PSS232 as potential mGluR5 binders. Synthesis. 2013;45:1877\u201385.","journal-title":"Synthesis"},{"key":"3879_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00259-014-2883-7","volume":"42","author":"S Milicevic Sephton","year":"2015","unstructured":"Milicevic Sephton S, Herde M\u00fcller A, Mu L, Keller C, R\u00fcdis\u00fchli S, Auberson Y, et al. Preclinical evaluation and test-retest studies of [(18)F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5). Eur J Nucl Med Mol Imaging. 2015;42:128\u201337. https:\/\/doi.org\/10.1007\/s00259-014-2883-7 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3879_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/jnc.13001","volume":"133","author":"A M\u00fcller Herde","year":"2015","unstructured":"M\u00fcller Herde A, Keller C, Milicevic Sephton S, Mu L, Schibli R, Ametamey SM, et al. Quantitative positron emission tomography of mGluR5 in rat brain with [(18) F]PSS232 at minimal invasiveness and reduced model complexity. J Neurochem. 2015;133:330\u201342. https:\/\/doi.org\/10.1111\/jnc.13001 .","journal-title":"J Neurochem"},{"key":"3879_CR27","first-page":"1069","volume":"30","author":"E Meyer","year":"1989","unstructured":"Meyer E. Simultaneous correction for tracer arrival delay and dispersion in CBF measurements by the H215O autoradiographic method and dynamic PET. J Nucl Med. 1989;30:1069\u201378.","journal-title":"J Nucl Med"},{"key":"3879_CR28","unstructured":"Kr\u00e4mer SD, Betzel T, Mu L, Haider A, Herde M\u00fcller A, Boninsegni AK, et al. Evaluation of 11C-Me-NB1 as a potential PET radioligand for measuring GluN2B-containing NMDA receptors, drug occupancy and receptor crosstalk. J Nucl Med. in press."},{"issue":"9","key":"3879_CR29","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","volume":"27","author":"RB Innis","year":"2007","unstructured":"Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533. https:\/\/doi.org\/10.1038\/sj.jcbfm.9600493 .","journal-title":"J Cereb Blood Flow Metab"},{"key":"3879_CR30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","volume":"10","author":"J Logan","year":"1990","unstructured":"Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time\u2013activity measurements applied to [N-11C-methyl]-(\u2212)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740\u20137. https:\/\/doi.org\/10.1038\/jcbfm.1990.127 .","journal-title":"J Cereb Blood Flow Metab"},{"key":"3879_CR31","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834\u201340. https:\/\/doi.org\/10.1097\/00004647-199609000-00008 .","journal-title":"J Cereb Blood Flow Metab"},{"key":"3879_CR32","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"AC-19","author":"H Akaike","year":"1974","unstructured":"Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;AC-19:716\u201323.","journal-title":"IEEE Trans Autom Control"},{"key":"3879_CR33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/biomet\/76.2.297","volume":"76","author":"CM Hurvich","year":"1989","unstructured":"Hurvich CM, Tsai C-L. Regression and time series model selection in small samples. Biometrika. 1989;76:297\u2013307.","journal-title":"Biometrika"},{"key":"3879_CR34","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2967\/jnumed.107.039578","volume":"48","author":"V Treyer","year":"2007","unstructured":"Treyer V, Streffer J, Wyss MT, Bettio A, Ametamey SM, Fischer U, et al. Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med. 2007;48:1207\u201315. https:\/\/doi.org\/10.2967\/jnumed.107.039578 .","journal-title":"J Nucl Med"},{"key":"3879_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejps.2015.10.013","volume":"87","author":"SD Kr\u00e4mer","year":"2016","unstructured":"Kr\u00e4mer SD. Quantitative aspects of drug permeation across in vitro and in vivo barriers. Eur J Pharm Sci. 2016;87:30\u201346. https:\/\/doi.org\/10.1016\/j.ejps.2015.10.013 .","journal-title":"Eur J Pharm Sci"},{"key":"3879_CR36","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/syn.20445","volume":"61","author":"JQ Wang","year":"2007","unstructured":"Wang JQ, Tueckmantel W, Zhu A, Pellegrino D, Brownell AL. Synthesis and preliminary biological evaluation of 3-[(18)F]fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5. Synapse. 2007;61:951\u201361. https:\/\/doi.org\/10.1002\/syn.20445 .","journal-title":"Synapse"},{"key":"3879_CR37","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00259-015-3301-5","volume":"43","author":"RL Pillai","year":"2016","unstructured":"Pillai RL, Tipre DN. Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging. Eur J Nucl Med Mol Imaging. 2016;43:1151\u201370. https:\/\/doi.org\/10.1007\/s00259-015-3301-5 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3879_CR38","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1038\/tp.2013.46","volume":"3","author":"SH Fatemi","year":"2013","unstructured":"Fatemi SH, Folsom TD, Rooney RJ, Thuras PD. mRNA and protein expression for novel GABAA receptors theta and rho2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry. 2013;3:e271. https:\/\/doi.org\/10.1038\/tp.2013.46 .","journal-title":"Transl Psychiatry"},{"key":"3879_CR39","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1007\/s00429-014-0812-y","volume":"220","author":"B Gulyas","year":"2015","unstructured":"Gulyas B, Sovago J, Gomez-Mancilla B, Jia Z, Szigeti C, Gulya K, et al. Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brain. Brain Struct Funct. 2015;220:3043\u201351. https:\/\/doi.org\/10.1007\/s00429-014-0812-y .","journal-title":"Brain Struct Funct"},{"key":"3879_CR40","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.nucmedbio.2007.07.009","volume":"34","author":"S Patel","year":"2007","unstructured":"Patel S, Hamill TG, Connolly B, Jagoda E, Li W, Gibson RE. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. Nucl Med Biol. 2007;34:1009\u201317. https:\/\/doi.org\/10.1016\/j.nucmedbio.2007.07.009 .","journal-title":"Nucl Med Biol"},{"key":"3879_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/jcbfm.2009.190","volume":"30","author":"VJ Cunningham","year":"2010","unstructured":"Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46\u201350. https:\/\/doi.org\/10.1038\/jcbfm.2009.190 .","journal-title":"J Cereb Blood Flow Metab"},{"key":"3879_CR42","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.nucmedbio.2010.04.107","volume":"37","author":"C Burger","year":"2010","unstructured":"Burger C, Deschwanden A, Ametamey S, Johayem A, Mancosu B, Wyss M, et al. Evaluation of a bolus\/infusion protocol for 11C-ABP688, a PET tracer for mGluR5. Nucl Med Biol. 2010;37:845\u201351. https:\/\/doi.org\/10.1016\/j.nucmedbio.2010.04.107 .","journal-title":"Nucl Med Biol"},{"key":"3879_CR43","doi-asserted-by":"crossref","unstructured":"Rostomian, A.H., Madison, C., Rabinovici, G.D., Jagust, W.J., 2011. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 52:173\u2013179","DOI":"10.2967\/jnumed.110.082057"},{"key":"3879_CR44","doi-asserted-by":"crossref","unstructured":"Ing-Tsung Hsiao, Chin-Chang Huang, Chia-Ju Hsieh, Shiaw-Pyng Wey, Mei-Ping Kung, Tzu-Chen Yen, Kun-Ju Lin, (2013) Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45\/Amyvid) PET. European Journal of Nuclear Medicine and Molecular Imaging 40 (6):908\u2013920","DOI":"10.1007\/s00259-013-2350-x"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-017-3879-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3879-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3879-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T14:29:46Z","timestamp":1751034586000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-017-3879-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["3879"],"URL":"https:\/\/doi.org\/10.1007\/s00259-017-3879-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]}}}